Lassiter Wright III 4

What Happened

Lassiter Wright III, a director of Quest Diagnostics (DGX), reported an acquisition of 6 shares on April 20, 2026 at $194.70 per share, for a total value of about $1,168. The Form 4 covering this transaction was filed on April 24, 2026. This is a small purchase and appears routine rather than a material insider bet.

Key Details

• Transaction date and price: Apr 20, 2026 — 6 shares at $194.70 each (total ≈ $1,168).
• Filing date / timeliness: Form 4 filed Apr 24, 2026; the filing shows a timeliness code "L" (late).
• Shares owned after transaction: Not specified in the filing.
• Footnotes in the filing:
  • F1: Represents an award of restricted share units (RSUs).
  • F2: These shares reflect acquisition under a dividend reinvestment plan (DRIP); such DRIP shares are often eligible for deferred reporting on Form 5 under Rule 16a-6, but the reporting person chose to report them on this Form 4.

Context

• The amount is small (~$1.2k) and is commonly associated with DRIP or routine director share purchases rather than a strategic new position.
• Purchases by insiders can be a bullish signal, but small DRIP or reinvestment transactions are generally considered routine and not a strong market indicator.
• No indication of option exercises, gifts, or immediate sales in this transaction.